PRAME ‐Positive Eruptive Melanocytic Nevi in the Setting of BRAF ‐Inhibitors
Journal of Cutaneous Pathology · 2026
DOI: 10.1111/cup.70111 ↗Kurz gefasst
Fallbericht in der Zeitschrift Journal of Cutaneous Pathology, 2026. Verfasst von Maxine M Mackie und 3 weiteren Autor:innen. Beteiligte Einrichtung: Columbia Vagelos College of Physicians and Surgeons, Columbia University, New York, New York, USA. Hauptthemen laut MEDLINE: Antigens, Neoplasm, Carbamates, Nevus, Pigmented, Proto-Oncogene Proteins B-raf. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 16 Literaturangaben.
Abstract (Originalsprache)
Preferentially Expressed Antigen in Melanoma (PRAME) is an immunohistochemical marker utilized in the diagnosis of melanocytic neoplasms. While still considered highly specific, both diffuse and variable PRAME immunoreactivity have been demonstrated in benign melanocytic lesions. This phenomenon is widely documented, as well as the phenomenon of eruptive melanocytic nevi (EMN) arising in the context of BRAF‐inhibition. We report here a patient on encorafenib who developed numerous new pigmented lesions within 3 weeks of therapy. Initial biopsy suggested evolving melanoma in situ with 70%–75% intraepidermal melanocytes strongly PRAME positive, prompting additional testing. Two subsequent lesions demonstrated only focal PRAME staining and lacked malignant features, leading to the reclassification of the initial lesion as a compound nevus with unusual features. This case underscores that BRAF inhibition may enhance PRAME expression in benign melanocytic nevi, potentially through mechanisms involving mitogen‐activated protein kinase (MAPK) activation, altered Erk phosphorylation, or disruption of retinoic acid (RA) signaling. This case also brings awareness to the potential of medication‐induced PRAME expression and encourages both dermatologists and dermatopathologists to avoid overdiagnosis as PRAME continues to gain prominence as a diagnostic biomarker.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Columbia Vagelos College of Physicians and Surgeons, Columbia University, New York, New York, USA.
- Department of Dermatology, Columbia University Irving Medical Center, New York, New York, USA.
ORCID-Profile: Maxine M Mackie
Zitieren
APA
Mackie, M. M., Husain, S., Gru, A. A., & Gallitano, S. M. (2026). PRAME ‐Positive Eruptive Melanocytic Nevi in the Setting of BRAF ‐Inhibitors. Journal of Cutaneous Pathology. https://doi.org/10.1111/cup.70111
Vancouver
Mackie MM, Husain S, Gru AA, Gallitano SM. PRAME ‐Positive Eruptive Melanocytic Nevi in the Setting of BRAF ‐Inhibitors. Journal of Cutaneous Pathology. 2026. doi:10.1111/cup.70111
BibTeX
@article{Mackie2026,
author = {Mackie, Maxine M and Husain, Sameera and Gru, Alejandro A and Gallitano, Stephanie M},
title = {PRAME ‐Positive Eruptive Melanocytic Nevi in the Setting of BRAF ‐Inhibitors},
journal = {Journal of Cutaneous Pathology},
year = {2026},
doi = {10.1111/cup.70111}
}
EUVIMED